Akebia Therapeutics (AKBA)
NASDAQ:AKBA
Want to see AKBA full AI Analyst Report?
Earnings Data
Report Date
Jul 30, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.04Last Year’s EPS
0Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call highlights strong commercial momentum for Vafseo (32% revenue growth, ~60% patient growth quarter-over-quarter, higher prescriber engagement and improved adherence under observed dosing) and meaningful pipeline progress with supportive clinical data and upcoming readouts. However, legacy product Auryxia faces notable generic-driven revenue decline (≈-17%), the company swung to a net loss in the quarter, experienced sizable inventory write-downs and higher operating expenses, and cash declined q/q. While the launch and clinical developments are encouraging and provide a clear growth narrative, the near-term financial headwinds and competitive/enrollment risks temper the outlook.Company Guidance
Strong Vafseo Quarterly Revenue Growth
Vafseo net product revenues were $15.8M in Q1 2026 versus $12.0M in Q1 2025, a 32% year-over-year increase and the highest quarter of Vafseo revenue to date.
Rapid Patient and Prescriber Adoption
Patients on Vafseo increased nearly 60% quarter-over-quarter to ~7,500 at the end of Q1 2026 (vs end of Q4 2025). Approximately 1,025 prescribers wrote scripts in Q1, ~28% higher than Q4 2025, and ~30% of prescribers were from dialysis organizations other than USRC.
Improved Adherence with Observed Dosing
Approximately two-thirds of Vafseo patients were treated 3x weekly by quarter end. First-refill adherence for patients under observed dosing protocols was ~86%, consistent with historical 85–90% levels and expected to remain stable as adoption scales.
Favorable Real-World and Clinical Evidence
Post-hoc INNOVATE analysis published in JASN showed lower risk of death or hospitalization for Vafseo vs ESA. Economic analysis indicated 7.7% fewer hospitalization events, a 16% reduction in hospitalization days, and a 14.8% lower annual hospitalization cost (Medicare-based) for Vadadustat-treated patients.
Ongoing and Upcoming Clinical Milestones
VOCAL topline results (DaVita clinics, 3x weekly dosing) expected by year-end 2026; VOICE topline expected early 2027. Multiple pipeline programs advancing: praliciguat Phase II (FSGS, up to ~60 patients), AKB-097 (Abribafisp) Phase II basket trial planned H2 2026, and AKB-9090 Phase I initiated with topline expected early 2027.
Commercial Momentum Beyond Initial Provider
Adoption is broadening across dialysis organizations: USRC, IRC and DCI progressed to observed dosing with rapid uptake; DaVita showing growth and expected to move to observed dosing in H2 2026, representing a large addressable opportunity.
Strategic R&D Positioning and Investor Engagement
R&D Day in April showcased preclinical and clinical data (praliciguat, AKB-097) with positive reception from clinical experts; company emphasizes kidney-disease focused pipeline as a multi-product, long-term value driver.
Sufficient Near-Term Liquidity
Cash and cash equivalents were $162.6M as of March 31, 2026. Company expects existing cash resources and cash from operations to fund the current operating plan for at least two years.
AKBA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AKBA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2026 | $1.48 | $1.18 | -20.27% |
Feb 26, 2026 | $1.21 | $1.32 | +9.09% |
Nov 10, 2025 | $2.04 | $1.67 | -18.14% |
Aug 07, 2025 | $3.79 | $3.01 | -20.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Akebia Therapeutics (AKBA) report earnings?
Akebia Therapeutics (AKBA) is schdueled to report earning on Jul 30, 2026, After Close (Confirmed).
What is Akebia Therapeutics (AKBA) earnings time?
Akebia Therapeutics (AKBA) earnings time is at Jul 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AKBA EPS forecast?
AKBA EPS forecast for the fiscal quarter 2026 (Q2) is -0.04.